Rheumatology Vol. I: Inflammatory Arthritis
Three topics, 43 cases — choose one below to browse its cases.
Conventional and biologic DMARD sequencing after methotrexate failure, JAK inhibitor cardiovascular and thrombotic risk stratification, perioperative and pregnancy-related therapy adjustment, vaccination timing around B-cell depletion, and glucocorticoid-tapering strategy in early and difficult-to-treat disease
Allopurinol vs. febuxostat selection under cardiovascular and renal constraints, pegloticase co-therapy and transition strategy, IL-1 inhibitor use when standard flare therapy is contraindicated, urate-lowering treatment thresholds, and CPPD flare and chronic-phenotype management under renal impairment
First- and second-biologic selection across axial spondyloarthritis and psoriatic arthritis, TNF vs. IL-17 vs. JAK inhibitor choice under comorbidity constraints (IBD, cardiovascular risk, latent TB, uveitis), and biologic tapering and eligibility-threshold decisions